checkAd
    Startseite > Aktien > Cardiff Oncology > Nachrichten
    Cardiff Oncology Aktie
    2,9300
     
    USD
    -1,68 %
    -0,0500 USD
    Letzter Kurs 08.06.24 Nasdaq
    2,9300
     
    USD
    100 STK
    Geldkurs 07.06.24
    2,9400
     
    USD
    400 STK
    Briefkurs 07.06.24
    ISIN: US14147L1089 · WKN: A2P4GU · SYM: CRDF · USA

    Neueste Nachrichten

    Cardiff Oncology to Present at the Jefferies Healthcare Conference
    29.05.24 · globenewswire · Cardiff Oncology
    Cardiff Oncology to Present at Upcoming Investor Conferences in May
    13.05.24 · globenewswire · Cardiff Oncology
    Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
    02.05.24 · globenewswire · Cardiff Oncology
    Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
    25.04.24 · globenewswire · Cardiff Oncology
    Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
    08.04.24 · globenewswire · Cardiff Oncology
    Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
    06.03.24 · globenewswire · Cardiff Oncology
    Fokus Aktien mit extremen Handelsvolumen am Freitag, den 01.03.2024
    01.03.24 · wO Chartvergleich · Biotest
    Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
    29.02.24 · globenewswire · Cardiff Oncology
    Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
    29.02.24 · globenewswire · Cardiff Oncology
    Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
    29.02.24 · globenewswire · Cardiff Oncology
    Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
    26.02.24 · globenewswire · Cardiff Oncology
    Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
    22.02.24 · globenewswire · Cardiff Oncology